Talin Boghosian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Talin Boghosian has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alicia A. Tone
Ovarian Cancer Canada, Toronto, ON M2P 2A9, Canada
1 shared publication - Alison Ross
Ovarian Cancer Canada, 145 Front St E #205, Toronto, ON M5A 1E3, Canada
1 shared publication - Alon D. Altman
Division of Gynecologic Oncology, Winnipeg Women’s Hospital, University of Manitoba, Winnipeg, MB R3E 0L8, Canada
1 shared publication - Cailey Crawford
Ovarian Cancer Canada, 145 Front St E #205, Toronto, ON M5A 1E3, Canada
1 shared publication - Elisabeth Baugh
School of Continuing Studies, University of Toronto, 158 St. George St., Toronto, ON M5S 2V8, Canada
1 shared publication - Frances Reid
World Ovarian Cancer Coalition, Toronto, Canada
1 shared publication
Latest Publications
- Open Access
- 5 May 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (5) , 3318-3340
Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman StudyTM
The Every Woman StudyTM: Canadian Edition is the most comprehensive study to date exploring patient-reported experiences of ovarian cancer (OC) on a national scale. An online survey conducted in Fall 2020 included individuals diagnosed with OC in Canada, reporting responses from 557 women from 11 Canadian provinces/territories. Median age at diagnosis was 54 (11–80), 61% were diagnosed between 2016–2020, 59% were stage III/IV and all subtypes of OC were represented. Overall, 23% had a family history of OC, 75% had genetic testing and 19% reported having a BRCA1/2 mutation. Most (87%) had symptoms prior to diagnosis. A timely diagnosis of OC (≤3 months from first presentation with symptoms) was predicted by age (>50) or abdominal pain/persistent bloating as the primary symptom. Predictors of an acute diagnosis (<1 month) included region, ER/urgent care doctor as first healthcare provider or stage III/IV disease. Regional differences in genetic testing, treatments and clinical trial participation were also noted. Respondents cited substantial physical, emotional, practical and financial impacts of an OC diagnosis. Our national survey has revealed differences in the pathway to diagnosis and post-diagnostic care among Canadian women with OC, with region, initial healthcare provider, specific symptoms and age playing key roles. We have identified many opportunities to improve both clinical and supportive care of OC patients across the country.
- 5 May 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (5) , 3318-3340
Open AccessUnderstanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman StudyTM
The Every Woman StudyTM: Canadian Edition is the most comprehensive study to date exploring patient-reported experiences of ovarian cancer (OC) on a national scale. An online survey conducted in Fall 2020 included individuals diagnosed with OC in Canada, reporting responses from 557 women from 11 Canadian provinces/territories. Median age at diagnosis was 54 (11–80), 61% were diagnosed between 2016–2020, 59% were stage III/IV and all subtypes of OC were represented. Overall, 23% had a family history of OC, 75% had genetic testing and 19% reported having a BRCA1/2 mutation. Most (87%) had symptoms prior to diagnosis. A timely diagnosis of OC (≤3 months from first presentation with symptoms) was predicted by age (>50) or abdominal pain/persistent bloating as the primary symptom. Predictors of an acute diagnosis (<1 month) included region, ER/urgent care doctor as first healthcare provider or stage III/IV disease. Regional differences in genetic testing, treatments and clinical trial participation were also noted. Respondents cited substantial physical, emotional, practical and financial impacts of an OC diagnosis. Our national survey has revealed differences in the pathway to diagnosis and post-diagnostic care among Canadian women with OC, with region, initial healthcare provider, specific symptoms and age playing key roles. We have identified many opportunities to improve both clinical and supportive care of OC patients across the country.